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Abstract 
Objectives: To compare the maternal and perinatal outcomes of ursodeoxycholic acid with placebo in obstetric 
cholestasis. 
Materials and Methods: It was an open randomized parallel-group study with convenient sampling, conducted 
at Pakistan ordinance factories hospital (POF Hospital) Wah Cantt, from 1st June 2016-30th May 2019. Patients with 
obstetric cholestasis of pregnancy, diagnosed between 24-34 weeks of gestation, were randomized to receive 
either ursodeoxycholic acid 500mg twice daily or placebo one capsule twice daily for 4 weeks. The data was 
collected on a pre-designed proforma. The data of 84 patients, who full fill the inclusion criteria were analyzed 
using SPSS vs 19. Maternal outcomes measured were a relief in pruritus and a decrease in hepatic alanine 
aminotransferase levels (ALT) at the end of 2 weeks and 4 weeks of treatment.  The mode of delivery was noted. 
Fetal outcomes measured were meconium staining of amniotic fluid and the need for neonatal intensive care unit 
(NICU) admission. 
Results: The results showed significant improvement in maternal itch score (P=0.001) and serum transaminases 
level (p=0.001) in patients using UDCA as compared to placebo. Although there were less number of caesarean 
sections (p=0.36), meconium-stained liquor (p=0.29) and NICU admissions (P=0.33) in the UDCA group the 
differences were not statistically significant.  
Conclusion: Treatment with UDCA in obstetric cholestasis improved maternal complaint of itching and 
decreased raised transaminases levels but did not affect significantly the mode of delivery, incidence of 
meconium-stained liquor and NICU admissions. 
Keywords: Obstetric cholestasis, Ursodeoxycholic acid, perinatal outcome, Pruritus. 
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Introduction 
 
Obstetric cholestasis also labelled as intrahepatic 
cholestasis of pregnancy is not an uncommon liver 
disorder that has adverse effects on both mother and 
fetus.1 The disease Prevalence varies due to genetic 
and environmental differences in population from 
0.7%-5%.2  Women present, usually in the second and 
third trimester, with severe itching especially on palms 
and soles but there is no rash.3 There is an elevation in 
serum transaminases and bile acid levels.4The 
diagnosis is made after excluding other causes of 
pruritus and deranged liver functions.5  Complication 
increase if disease start before 33 weeks of gestation.6 
  In addition to maternal discomfort and sleep 
disturbance due to pruritus, the studies have shown 
increased fetal and perinatal risks which include 
prematurity, low birth weight, meconium staining of 
amniotic fluid, fetal distress, increased risk of NICU 
admission and stillbirth.7, 8, 9, 10, 11 
While prescribing medications, the obstetrician has to 
take into consideration the maternal symptomatic 
relief as well as its effect on perinatal outcome. Many 
drugs have been tried to treat obstetric cholestasis with 
variable efficacy. These include activated Charcoal, 
Guar gum, Dexamethasone, S-adenosylmethionine 
(SAMe) and ursodeoxycholic acid (UDCA).12 
 Ursodeoxycholic acid (UDCA), a commonly used 
drug, is a secondary bile acid that is naturally 
occurring but can be chemically synthesized. UDCA 
may play a role in the liver in a variety of ways. These 
related pathways include changes in bile acid’s Pool, 
choleresis, immune regulation, and cytoprotection 
mechanism.13,14 it is available in the form of capsules 
for oral use.  
Controversies still exist regarding the management of 
patients having obstetric cholestasis. Some 
obstetricians only advise simple emollients and anti-
allergic for itch relief while others favour the use of 
UDCA. Studies done so far, comparing UDCA with 
other drugs or placebos, have shown variable results, 
especially concerning the perinatal outcome. 15-23 
Due to these debates in the management of patients 
having obstetric cholestasis we planned this study. We 
compared the UDCA with placebo and observed the 
effects on maternal symptoms of pruritus, biochemical 
marker i.e. serum transaminase level, caesarean 
section rate, meconium staining of liquor and NICU 
admission.   
 
 
Materials and Methods 
 
An open, randomized, parallel-group study was 
performed comparing the efficacy and safety of 
ursodeoxycholic acid and placebo in obstetric 
cholestasis. The study was approved by the ethical 
committee of POF hospital Wah Cantt. The duration of 
study was 3 years from1st June 2016 to 30th May 2019. 
Sampling Technique was convenient sampling. 
Patients with a history of skin pruritus starting in the 
second and third trimester (between 24-34 weeks of 
gestation) characteristically involving palms and, soles 
with an elevation of alanine aminotransferase (ALT) 
above 45 IU /L, singleton pregnancy, no known lethal  
fetal anomaly and able to give written informed 
consent were included in the study. Exclusion criteria 
were patients having chronic liver disease, hepatic 
viral infections (HAV, HBV, HCV, cytomegalovirus, 
herpes simplex virus, and Epstein-Barr virus), skin 
diseases, allergic disorders, symptomatic cholelithiasis, 
history of previous caesarean section and multiple 
gestations. 
 All patients gave written informed consent before 
inclusion into the study and were randomized to 
receive either UDCA capsule 500mg twice daily 
(Group A) or placebo one capsule BD (Group B) for 4 
weeks. Placebos were provided by the pharmaceutical 
company providing capsule Urso. They were of the 
same size, shape, and colour. Randomization was 
performed by using sealed envelopes by the doctor 
attending the patient. All the information were 
collected on a pre-designed proforma   
Primary study outcomes were maternal symptomatic 
relief by measuring itch score and decline in hepatic 
alanine aminotransferase after 2 weeks and 4 weeks of 
treatment.  
Secondary outcomes measured were the outcome of 
pregnancy (mode of delivery, meconium staining of 
liquor, and need for NICU admission). Self-assessment 
of pruritus intensity was performed two weekly by use 
of numeric rating scale (NRS) The NRS has only one 
item and has the numbers 0 (“no itch”) to 10 (“worst 
imaginable itch”). Patients were requested to rate the 
intensity of their itch on an average in the past 1-3 
days using this scale and it was noted on their 
proforma.  
Liver function tests were done at the time of diagnosis 
and repeated after 2 weeks and 4 weeks by routine 
laboratory techniques. The decision to induce labour 
and carry out caesarean section was made by the 
managing obstetrician independently of this study.  
The mode of delivery, colour of liquor and need for 
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NICU admission were noted by the doctor present at 
delivery on the proforma. 
Statistical analysis was performed using SPSS version 
19. Numerical variables were analyzed using one way 
ANOVA test and descriptive variables were analyzed 
using the Chi-square test at 5 percent significant value. 
 
Results 
 
Total of ninety patients aged 18-40 years between 
24weeks and 34 weeks of gestation who fulfilled the 
inclusion criteria were enrolled in the study. Later on, 
six patients were excluded from the study because two 
were lost from follow up and four patients delivered 
before completion of 4 weeks of treatment. In the final 
analysis, 42 patients who received UDCA 500mg BD 
(Group A) and 42 patients who received placebos 
(Group B) for 4 weeks were included.  
The mean age of patients in the study group was 
28.34±4.31years. The mean gestational age at the onset 
of treatment was 31.68±1.71week. The mean parity of 
the study population was 3.27±1.74. 
The baseline variables of both groups didn’t differ 
between the two groups as shown in Table 1. 
 
Table 1: Baseline characteristics of treatment groups 
Characteristics UDCA 
Group 
(mean ± 
SD) 
Placebo  
group 
(mean ± SD) 
p-
value 
Age of patient  
(years) 
28.30 ± 3.61 28.37 ± 4.96 0.945 
Parity of 
patient 
3.26 ± 1.69 3.28 ± 1.81 0.951 
Gestational 
age at start of 
treatment 
(weeks) 
31.73 ± 1.87 31.64 ± 1.55 0.820 
 
The intensity of itch was similar in two groups at 
baseline 8.42±0.88 vs 8.80±0.99 (p=0.067). Analysis of 
change in itch score between two groups at baseline 
and after 2 weeks showed significant improvement in 
the UDCA group compared with the placebo group 
and the difference was even more marked after 4 
weeks of treatment (Table 2). 
 
 
 
 
Table 2: Comparison of itch score between groups 
Itch score UDCA 
Group mean 
± SD 
Placebo  
Group mean 
± SD 
P-
value 
Before 
treatment 
8.80±0.99 8.42±0.88 0.067 
After 2 
weeks 
4.69±1.15 7.23±0.75 0.001 
After 4 
weeks 
2.19±0.94 6.23±1.07 0.001 
 
Table 3 shows mean ALT levels at the start of 
treatment, 2 weeks and 4 weeks after starting of 
treatment in the two groups. 
 
Table 3: Comparison of ALT levels in two groups 
Biochemical 
marker 
(ALT levels) 
UDCA group 
(mean ± SD) 
Placebo Group 
(mean ± SD) 
p-
value 
At start of 
treatment 
191.45 ± 61.42 166.85 ± 41.00 0.034 
After 2 
weeks 
93.73 ± 35.08 152.50 ± 38.39 0.000 
After 4 
weeks 
58.16 ± 15.71 149.00 ± 32.79 0.000 
 
In the UDCA group, 5 patients underwent LSCS 
compared to 8 in the placebo group. The main 
indication was meconium-stained liquor causing fetal 
distress. Although their caesarean section rate was 
high and more babies had meconium-stained liquor in 
the placebo group as compared to the UDCA group 
but it was not statistically significant. (Table 4)  
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Table 4: comparison of mode of delivery & perinatal 
outcome 
Parameters UDCA 
Group N 
(%) 
Placebo 
Group N 
(%) 
p-
value 
Mode of 
delivery 
SVD 37(88%) 34(81%) 0.365 
LSCS 5(12%) 8(19%) 
Meconium 
stained 
liquor 
Yes  3(7.1%) 6(14.2%) 0.29 
No  39(92.9%
) 
36(85.7%
) 
NICU 
Admissions 
Yes  4(9.5%) 7(16.7%) 0.332 
No  38(90.5%
) 
35(83.3%
) 
 
No stillbirths were observed in either group, and no 
significant difference between the two groups was 
observed concerning NICU admission. 
 
Discussion 
  
The goal of the management of women having 
obstetric cholestasis is to decrease maternal discomfort 
caused by itching and to prevent the harmful effects of 
the disease on fetuses and neonates. These harmful 
fetal effects are at present unpredictable by fetal 
surveillance methods of CTG, biophysical profile, and 
Doppler studies. The management of obstetric 
cholestasis varies among different obstetric units and 
even among obstetricians in the same units. Some 
prescribe ursodeoxycholic acid while other 
obstetricians insist on the use of simple emollients or 
anti-allergic drugs for itch control. 
This study which was a randomized controlled trial 
was an effort to resolve the issue of whether treatment 
with UDCA has a benefit for the mother and fetus. 
The mean age of women in our study is 28.34±4.31 
being 28.30±3.61 in the UDCA group and 28.37±4.96 in 
the placebo group. while a study by Medda S showed 
the mean age of 27.53±4.49years with most patients 
between the age group 26-30yrs.5 In a local study 
conducted at CMH Kharian Pakistan   mean age of 
women having obstetric cholestasis  calculated was 
29.8±4.76 years which is close to our observation.24 
Mean parity was 3.27±1.74 and 17(20.2%) patients 
were primigravida (9 in UDCA Group and 8 in the 
placebo group) and 67(79.8%) were multigravida (33 
in UDCA group and 34 in the placebo group). Esitu 
M.C. in her study showed a prevalence of 35.6% in 
primigravida patients and 64.4% in multigravida 
patients.25 A local study at Agha khan hospital Karachi 
also showed a high prevalence of 57% among 
primigravidas.26 The reason for this difference is not 
clear. 
Mean gestational age (weeks) in both groups at the 
time of diagnosis and start of the trial is 31.68±1.71 
being 31.73±1.87 in the UDCA group and 31.64±1.55 in 
the placebo group. The range was 24-34 weeks. The 
finding in our study was similar to the study by 
Medda S who also showed the mean gestational age of 
patients at diagnosis 31.80+4.39 weeks.5 Estiu MC 
showed mean gestational age at the time of diagnosis 
being 33.6±3.6 weeks with most cases diagnosed 
between 32 and 37 weeks.25 The reason for the lower 
mean gestational age at diagnosis is that we excluded 
cases diagnosed after 34 weeks from our study.  
 There was no statistically significant difference in 
maternal itch score at the start of treatment (p=0.067) 
but a marked improvement in maternal symptoms 
was observed after 2weeks in UDCA group compared 
with placebo (mean itch score: 4.69±1.15 vs 7.23±0.75) 
and there was further improvement after 4 weeks of 
treatment (mean itch score 2.19±0.94 vs 6.23±1.07). 
Kondrackiene J showed maternal pruritus was 
markedly improved with UDCA treatment compared 
to cholestyramine (pruritus score: 2.08±0.63 vs 
2.92±0.62; p-value 0.05) and the difference was more 
pronounced after 14 days (pruritus score: 0.44±0.65 vs 
1.88±0.98; p-value .001).15 Rodrigo Z and  Joutsiniemi T 
have also shown statistically significant improvement 
in maternal pruritus after UDCA treatment as 
compared to placebo.16,17 Study by Glantz A showed 
more itch improvement in the placebo group 
compared to UDCA.20 This may be because of a small 
sample size.   
There was a significant improvement in biochemical 
marker i.e. ALT levels after treatment with UDCA as 
compared to placebo. The mean ALT levels fell from 
191.45IU/L to 58.14 IU/L after 4 weeks of UDCA 
treatment. Similar results have been shown by Palma 
in his study of 15 patients after 3 weeks of treatment.18 
Although the number of patients in studies by Diaferia 
and Nicastri were small (16 in each study) but the 
results similar to our study were also observed by 
them.19, 20  
Bile acids levels are also used to diagnose and assess 
the severity of disease but as they were costly and not 
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available at our hospital, we could not include them in 
our study. 
 Although more patients in the placebo group(19%) 
required delivery by caesarean section as compared to 
the UDCA  group(12%), the main indication being 
fetal distress and meconium-stained liquor, but the 
difference did not reach the level of statistical 
significance (p=0.365). A meta-analysis of 4 trials 
including 210 women had also shown similar results.12 
In our study meconium-stained liquor was observed in 
14.2% patients on placebos and 7.1% patients on 
UDCA. The difference was not significant (p=0.29). 
Chappell L in his analysis of 111 patients noted 
meconium-stained liquor in 23.6 % ( 13/55) patients in 
the placebo group and 8.9 % ( 5/56) in the UDCA 
group (p=0.04%). 21 The reasons for this difference in 
result may be the difference in gestational age at 
delivery because it included cases who had early-term 
delivery and late-term delivery both while we 
followed the policy of routine induction of labour at 38 
weeks in patients diagnosed as obstetric cholestasis.  
Only 9.52% of babies (4/42) required admission in 
NICU in the UDCA group as compared to 16.6% 
(7/42) in the placebo group (p=0.332). The same was 
observed by Chappell L where 8.3%(5/60) and 
17.1%(11/64) babies in the UDCA group and placebo 
group required NICU admission respectively 
(p=0.15).21 Although this difference is not statistically 
significant it shows less need for NICU admission in 
the UDCA group. 
This study showed clear maternal benefits of UDCA in 
improving maternal itch. The treatment also decreased 
pathologically raised serum ALT levels, showing 
improvement in biochemical markers. Although there 
was a reduction in caesarean section rate, meconium 
staining of liquor and NICU admission but the benefit 
was not significant statistically. The limitation of our 
study was that we only studied serum ALT levels due 
to the easy availability and cost-effectiveness of this 
test and did not include serum bile acid levels. Further 
multicenter studies with a large sample size are 
required to establish any fetal and neonatal benefits of 
UDCA treatment as well as its effect on birth weight.  
 
Conclusion 
  
The results of our study recommend the use of UDCA 
for decreasing the severity of discomfort caused by 
itching and for improving liver function and 
recommend more studies to establish benefit for the 
perinatal outcome.   
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